The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.
A new study published in JAMA Cardiology reveals that approximately 90% of ischemic heart disease deaths in the United States remain attributable to modifiable risk factors including blood pressure, diet, and LDL cholesterol, despite significant declines in mortality since 1990. Research also shows these factors are linked to unstable coronary artery plaques that lead to heart attacks.
Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.